ALMS – alumis inc. (US:NASDAQ)

News

Alumis to Present at the Leerink Partners Global Healthcare Conference
Alumis Shares Phase 3 Psoriasis Details, Targets 2H NDA Filing at Oppenheimer Healthcare Conference [Yahoo! Finance]
Alumis (ALMS) is now covered by Stifel Nicolaus. They set a "buy" rating and a $44.00 price target on the stock.
Alumis to Participate in Upcoming February Investor Conferences
Alumis (NASDAQ:ALMS) was upgraded by analysts at Chardan Capital to a "strong-buy" rating.
Show more
Live Event: Join our next subscriber-only event: "The Data Driven Investor"
Register for our next upcoming LIVE training session, which will be hosted on Tuesday April 24th at 08:00 PM EST (New York Time).
Get your questions answered during the Q & A session.
For any support questions, contact our team: support@newsquantified.com